Drug profile · INN
nitric oxide
INOMAX
nitric oxide (INOMAX) is a soluble guanylate cyclase activator. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — nitric oxide
- US status
- approved
- Class
- Respiratory system (R07)
- Route
- INHALATION
- Patents
- 20
- Programs
- 2
- Data quality
- 0.84
Quick answer
nitric oxide (INOMAX) is a soluble guanylate cyclase activator. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Soluble guanylate cyclase activator
Primary target: Soluble guanylate cyclase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12286405
Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase
granted -
US 12251449
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
granted -
US 12213973
Bacterial nitric oxide synthase inhibitors
granted -
US 12083113
Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
granted -
US 11998513
Two-part nitric oxide generating topical compositions
granted -
US 11439632
Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
granted -
US 11439609
Nitric oxide releasing PLGA microspheres for biomedical applications
granted -
US 11413420
Nitric oxide delivery devices
granted -
US 11241406
Compositions and methods for acutley raising nitric oxide levels
granted -
US 11103622
Thromboresistant/bactericidal s-nitroso-n-acetylpenicillamine (SNAP)-doped nitric oxide release polymers with enhanced stability
granted -
US 10759791
Mammalian and bacterial nitric oxide synthase inhibitors
granted -
US 10543337
Nitric oxide delivery devices
granted -
US 10471109
Compositions and methods for promoting nitric oxide production through an oral delivery system
granted -
US 10342822
Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
granted -
US 9951014
Mammalian and bacterial nitric oxide synthase inhibitors
granted -
US 9878996
2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
granted -
US 9872953
Nitric oxide delivery devices
granted -
US 9821006
Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
granted -
US 9763974
Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
granted -
US 9765055
Intramolecular hydrogen-bonded nitric oxide synthase inhibitors
granted
Frequently asked questions
What is nitric oxide?
nitric oxide (INOMAX) is a soluble guanylate cyclase activator. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for nitric oxide?
INOMAX is a marketed brand name for nitric oxide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nitric oxide?
nitric oxide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.